{{Drugbox
| verifiedrevid = 437196684
| IUPAC_name = (2S)-3-ethynyl-5-(1-methylpyrrolidin-2-yl)pyridine
| image = Altinicline.svg
| width = 175

<!--Clinical data-->
| tradename =  
| routes_of_administration =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 179120-92-4
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 3036156
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2300234
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = RJ9V9V09VM
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 111659

<!--Chemical data-->
| C=12 | H=14 | N=2 
| molecular_weight = 186.252
| smiles = c2ncc(C#C)cc2C1CCCN1C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H14N2/c1-3-10-7-11(9-13-8-10)12-5-4-6-14(12)2/h1,7-9,12H,4-6H2,2H3/t12-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NUPUDYKEEJNZRG-LBPRGKRZSA-N
}}

'''Altinicline''' ('''SIB-1508Y''', '''SIB-1765F''') is a drug which acts as an [[agonist]] at neural [[nicotinic acetylcholine receptor]]s with high selectivity for the [[Alpha-4 beta-2 nicotinic receptor|α4β2]] subtype.<ref>{{Cite journal
| pmid = 10812948
| year = 2000
| last1 = Cosford | first1 = N. D.
| last2 = Bleicher
| last3 = Vernier
| last4 = Chavez-Noriega
| last5 = Rao
| last6 = Siegel
| last7 = Suto
| last8 = Washburn
| last9 = Lloyd
| title = Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist
| volume = 74
| issue = 2–3
| pages = 125–130 | first10 = I. A.
| journal = Pharmaceutica acta Helvetiae
| doi = 10.1016/S0031-6865(99)00024-2 | first2 = L.
| last10 = McDonald | first3 = J. M. | first4 = L. | first5 = T. S. | first6 = R. S. | first7 = C. | first8 = M. | first9 = G. K.
}}</ref><ref>{{Cite journal
| last1 = Wagner | first1 = F.
| last2 = Comins | first2 = D.
| title = Expedient five-step synthesis of SIB-1508Y from natural nicotine
| journal = The Journal of Organic Chemistry
| volume = 71
| issue = 22
| pages = 8673–8675
| year = 2006
| pmid = 17064057
| doi = 10.1021/jo0616052
}}</ref> It stimulates release of [[dopamine]] and [[acetylcholine]] in the brain in both rodent and primate models,<ref>{{Cite journal
| last1 = Rao | first1 = T.
| last2 = Adams | first2 = P.
| last3 = Correa | first3 = L.
| last4 = Santori | first4 = E.
| last5 = Sacaan | first5 = A.
| last6 = Reid | first6 = R.
| last7 = Cosford | first7 = N.
| title = Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist
| journal = Brain Research
| volume = 1234
| issue = 
| pages = 16–24
| year = 2008
| pmid = 18692487
| doi = 10.1016/j.brainres.2008.07.063
}}</ref> and progressed as far as Phase II [[clinical trials]] for [[Parkinson's disease]],<ref>The Parkinson Study Group. Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease. ''Neurology''. 2006;66:408-410. {{doi|10.1212/01.wnl.0000196466.99381.5c}}</ref> where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.

== References ==
{{Reflist}}

{{Stimulants}}
{{Nootropics}}
{{Nicotinic acetylcholine receptor modulators}}

[[Category:Nicotinic agonists]]
[[Category:Stimulants]]
[[Category:Pyridines]]
[[Category:Pyrrolidines]]
[[Category:Alkynes]]


{{nervous-system-drug-stub}}